<DOC>
	<DOCNO>NCT00921973</DOCNO>
	<brief_summary>The study ass safety , reactogenicity , tolerability VAX102 give Trivalent Inactivated Influenza Vaccine ( TIV ) deliver arm two separate IM injection healthy adult 18 49 year . The investigator measure immunogenicity VAX102 give TIV antibody response TIV give VAX102 compare TIV alone .</brief_summary>
	<brief_title>Safety VAX102 Vaccine Given With Seasonal Flu Vaccine Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female age 18 49 year inclusive Give write informed consent participate study adherence protocol requirement . Healthy , determine medical history , physical examination , vital sign , clinical safety laboratory examination Females willing practice birth control study . Women childbearing potential must negative urine pregnancy test within 24 hour precede receipt vaccination . Comprehension study requirement , express availability require study period , ability attend schedule visit . Did receive influenza vaccination ( TIV ) 20082009 influenza season . Presence significant acute chronic , uncontrolled medical psychiatric illness ( institution new medical surgical treatment , significant dose alteration uncontrolled symptom drug toxicity within 3 month ) determine medical history and/or physical exam . History cancer . History impaired immunoresponsiveness , include diabetes . Known hypersensitivity previous dose influenza vaccine allergy egg component study vaccine . Received influenza vaccination 20082009 season History systemic hypersensitivity reaction egg protein , component FLUVIRIN® , lifethreatening reaction previous influenza vaccination . Has know history GuillainBarré Syndrome Presently receive history receive medication treatment affect immune system allergy shot , immune globulin , interferon , immunomodulators , cytotoxic drug drug know frequently associate significant major organ toxicity , systemic corticosteroid ( oral injectable ) past 6 month . Inhaled topical corticosteroid allow . Participated clinical trial receive planned administration investigational compound within 30 day receive study vaccine and/or study Day 28 evaluation . Was vaccinate register vaccine within 14 day ( inactivated vaccine ) 28 day ( live vaccine ) prior receive study vaccine . History anaphylactic type reaction inject vaccine . History drug chemical abuse year study . Use new prescription medication start within 7 day study entry . Receipt blood product , include immunoglobulin , within 6 month administration study vaccine anticipate receipt study period . Donation blood blood product within 8 week study entry time study . Has clinical sign active infection and/or oral temperature ≥ 38 ( 100.4 ºF ) . Study entry may defer individual discretion investigator . Has evidence history ( within previous 12 month ) drug alcohol abuse . Any condition , opinion investigator , might interfere study objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>influenza</keyword>
	<keyword>universal influenza vaccine</keyword>
</DOC>